Insider Transactions in Q1 2025 at Scholar Rock Holding Corp (SRRK)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 24
2025
|
Erin Moore Interim PFO and PAO |
SELL
Open market or private sale
|
Direct |
13,564
-14.1%
|
$447,612
$33.12 P/Share
|
|
Mar 24
2025
|
Erin Moore Interim PFO and PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,564
+6.79%
|
$244,152
$18.69 P/Share
|
|
Mar 24
2025
|
Tracey Sacco Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,500
-4.22%
|
$214,500
$33.3 P/Share
|
|
Mar 24
2025
|
Tracey Sacco Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+6.01%
|
$50,000
$10.0 P/Share
|
|
Mar 17
2025
|
Katie Peng |
SELL
Open market or private sale
|
Direct |
1,006
-3.21%
|
$34,204
$34.42 P/Share
|
|
Mar 10
2025
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
142,292
-32.7%
|
$4,980,220
$35.34 P/Share
|
|
Mar 10
2025
|
Edward H Myles COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
112,897
+9.53%
|
$1,354,764
$12.5 P/Share
|
|
Mar 10
2025
|
Tracey Sacco Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,855
+27.55%
|
-
|
|
Mar 10
2025
|
Junlin Ho GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
32,145
+12.68%
|
-
|
|
Mar 10
2025
|
Jay T. Backstrom CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
113,570
+21.07%
|
-
|
|
Mar 10
2025
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
34,285
+25.25%
|
-
|
|
Mar 10
2025
|
Caryn Parlavecchio CHRO |
BUY
Grant, award, or other acquisition
|
Direct |
23,570
+12.58%
|
-
|
|
Mar 10
2025
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
32,145
+18.33%
|
-
|
|
Feb 19
2025
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
68,510
-14.54%
|
$2,534,870
$37.5 P/Share
|
|
Feb 19
2025
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
48,308
+6.83%
|
$434,772
$9.56 P/Share
|
|
Feb 18
2025
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
4,135
-3.05%
|
$148,860
$36.83 P/Share
|
|
Feb 18
2025
|
Caryn Parlavecchio CHRO |
SELL
Open market or private sale
|
Direct |
5,296
-3.64%
|
$190,656
$36.83 P/Share
|
|
Feb 18
2025
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
7,809
-5.26%
|
$281,124
$36.83 P/Share
|
|
Feb 18
2025
|
Junlin Ho GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
5,742
-2.94%
|
$206,712
$36.83 P/Share
|
|
Feb 18
2025
|
Jay T. Backstrom CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
18,372
-5.56%
|
$661,392
$36.83 P/Share
|
|
Jan 16
2025
|
Junlin Ho GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
9,039
-4.43%
|
$397,716
$44.2 P/Share
|
|
Jan 16
2025
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
12,539
-7.78%
|
$551,716
$44.2 P/Share
|
|
Jan 16
2025
|
Caryn Parlavecchio CHRO |
SELL
Open market or private sale
|
Direct |
6,434
-4.23%
|
$283,096
$44.2 P/Share
|
|
Jan 16
2025
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
7,347
-5.15%
|
$323,268
$44.2 P/Share
|
|
Jan 16
2025
|
Tracey Sacco Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,890
-7.89%
|
$171,160
$44.2 P/Share
|
|
Jan 16
2025
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,655
-7.76%
|
$248,820
$44.2 P/Share
|
|
Jan 16
2025
|
Jay T. Backstrom CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
22,308
-6.33%
|
$981,552
$44.2 P/Share
|